Company / Cash & Equivalents
RHYTHM PHARMACEUTICALS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$54.3M
FY2025
5-year range
$54.3M / $127.7M
FY2021-FY2025
Trend
-39.1%
vs FY2024
Sector context
#177 of 207
Health Care
What the data says
RHYTHM PHARMACEUTICALS, INC.'s cash & equivalents of $54M is lower than 86% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $7M in FY2016 to $128M in FY2022.
Based on SEC 10-K filings.
$54M in FY2025 with a 5-year CAGR of -11.6%.
Declined from $60M to $54M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -24.8%
- 5-Year CAGR
- -11.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 207This company $54.3M Sector average $669.5M
▼
-91.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 39.1% year-over-year.
- Ranks #177 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $54.3M | -39.1% |
| FY2024 | $89.1M | +48.4% |
| FY2023 | $60.1M | -52.9% |
| FY2022 | $127.7M | +115.5% |
| FY2021 | $59.2M | -41.3% |
| FY2020 | $100.9M | +61.9% |
| FY2019 | $62.3M | +25.7% |
| FY2018 | $49.5M | +44.7% |
| FY2017 | $34.2M | +423.5% |
| FY2016 | $6.5M | -81.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026